Phase II Study of First-Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971 - Concepedia

Concepedia

Publication | Closed Access

Phase II Study of First-Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971

295

Citations

14

References

2003

Year

Martin J. van den Bent, Alba A. Brandes, Johan Menten, Roger Stupp, M. Frénay, Olivier Chinot, Johan M. Kros, Carin C.D. van der Rijt, Ch.J. Vecht, Anouk Allgeier,

Journal of Clinical Oncology

Abstract

TMZ provides an excellent response rate with good tolerability in chemotherapy-naive patients with recurrent OD. A randomized phase III study comparing PCV with TMZ is warranted.

References

	Year	Citations

Page 1